FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| CARBOMETASPINE: protocol for a multicenter, prospective, randomized controlled trial of carbonfiber spinal fixation in metastatic disease. PMID 40898139 · BMC Cancer · 2025-Sep-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With Quizartinib. PMID 40892059 · Arch Pathol Lab Med · 2025-Sep-02 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. PMID 40847481 · J Am Heart Assoc · 2025-Sep-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial. PMID 40773205 · JAMA · 2025-Sep-02 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial. PMID 40569606 · Clin Cancer Res · 2025-Sep-02 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 2 Panel · risk unclear |
| Physical activity and mobility disability in older adult cancer survivors. PMID 40930715 · JNCI Cancer Spectr · 2025-Sep-01 The trial is a randomized clinical trial in older adults, but the intervention is a physical activity program, not a drug. While it includes cancer survivors as a subgroup, it is not a trial of a cancer treatment. Therefore, it does not meet the oncology drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis. PMID 40891895 · Oncologist · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial. PMID 40890873 · Cardiooncology · 2025-Sep-01 The record describes the rationale and design of a randomized clinical trial but explicitly states it is ongoing with no results. It is a protocol report. Furthermore, the primary endpoint is cardiotoxicity incidence, which is not a time-to-event oncology efficacy endpoint (e.g., OS, PFS). Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial. PMID 40890782 · Trials · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Optimizing short-term antibiotic treatment in patients with acute cholangitis: study protocol for an open-label randomized controlled trial (the BOLT-P3 trial). PMID 40890775 · Trials · 2025-Sep-01 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect of a self-made dietary therapy formula on the improvement of enteral feeding intolerance in patients with laryngeal cancer after surgery: A randomized controlled trial. PMID 40888947 · Support Care Cancer · 2025-Sep-01 The study is an oncology RCT with original results, but it is excluded because: (1) it does not have a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.)—the primary outcomes are complications and nutritional parameters; (2) the intervention is a non-drug dietary formula, not a drug; (3) the trial phase is not specified, and there is no signal for Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer. PMID 40888443 · Endocr Relat Cancer · 2025-Sep-01 Study is an eligible Phase III randomized drug trial in oncology, but its primary endpoints are pathological response scores (PEPI, EPclin), not a pre-specified time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or a Kaplan-Meier/HR analysis. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Managing, not lessening, uncertainty: a novel mind-body intervention for fear of cancer recurrence. PMID 40887510 · J Cancer Surviv · 2025-Sep-01 Excluded: Not a Phase III/IIIb or Phase II/III randomized trial; no drug intervention; primary/key endpoint is not time-to-event; intervention is non-drug psycho-oncology; report is secondary analysis of pilot study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials. PMID 40838872 · Oncologist · 2025-Sep-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer. PMID 40832988 · Cancer Res Commun · 2025-Sep-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Physical fitness and clinically assessed disease burden in long-term childhood cancer survivors-The SURfit study. PMID 40831029 · Cancer · 2025-Sep-01 The study is a randomized trial in human cancer survivors, but it is not a Phase III trial with a drug intervention. The primary endpoint is disease burden (adverse health outcomes) and its association with physical fitness, not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP. The intervention is physical activity/exercise, not a drug. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis. PMID 40773752 · J Basic Clin Physiol Pharmacol · 2025-Sep-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. PMID 40742738 · JAMA Oncol · 2025-Sep-01 The study is an oncology RCT with a drug intervention and original results, but it does not meet all required criteria: it is not a definitive Phase III trial, and its primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS) but a continuous measure of agitation severity. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial. PMID 40742733 · JAMA Oncol · 2025-Sep-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. PMID 40694530 · Diabetes Care · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease: A Randomized Noninferiority Trial. PMID 40658410 · JAMA Neurol · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical Trial. PMID 40638104 · JAMA Oncol · 2025-Sep-01 The record meets most eligibility criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original result). However, it fails the explicit requirement for a Phase III/IIIb or Phase II/III trial, as the phase is not clearly stated in the provided metadata. Therefore, is_eligible is set to false. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of sacubitril/valsartan in Afro-descendant patients with resistant hypertension: a randomized controlled trial. PMID 40621831 · J Hypertens · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Expected vs observed effect sizes for survival endpoints in phase 3 oncology trials. PMID 40600894 · J Natl Cancer Inst · 2025-Sep-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial. PMID 40560559 · JAMA Dermatol · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial. PMID 40560554 · JAMA Dermatol · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial. PMID 40543068 · Diabetes Care · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of tourniquet application on postoperative delirium in elderly patients undergoing total knee arthroplasty: a randomized clinical trial. PMID 40540295 · Int J Surg · 2025-Sep-01 This is a randomized clinical trial in humans, but it is not an oncology study (tourniquet use in total knee arthroplasty), lacks a time-to-event efficacy endpoint (primary outcome is incidence of delirium, not OS/PFS/etc.), and has no drug intervention (surgical/anesthesia-related). It does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults. PMID 40515653 · J Natl Cancer Inst · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Carcinogen reduction in a randomized controlled study comparing e-cigarette provision to assessment only among people with serious mental illness who smoke. PMID 40505215 · Drug Alcohol Depend · 2025-Sep-01 The study is a randomized trial in humans with original results, but it is not an oncology trial (focus is harm reduction via e-cigarette provision to reduce carcinogen exposure, not treatment of a human malignant neoplasm). It does not involve a drug-containing intervention (e-cigarette provision is a device, not a drug). It does not report a time-to-event efficacy endpoint (primary outcome is biomarker change in NNAL, not OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Optimal Head-of-Bed Positioning Before Thrombectomy in Large Vessel Occlusion Stroke: A Randomized Clinical Trial. PMID 40465238 · JAMA Neurol · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| NOVEMBER, A Phase 2 Trial of a 9-Day Course of Whole Breast Radiation Therapy With a Simultaneous Lumpectomy Boost for Early-Stage Breast Cancer. PMID 40314623 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial. PMID 40312101 · J Rheumatol · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies. PMID 40233987 · J Rheumatol · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated Versus Single-Session Radiosurgery to Preserve Hearing in Patients Affected by Sporadic Vestibular Schwannoma: The ACOUNEU Randomized Clinical Trial. PMID 40222395 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 The study is a randomized clinical trial in oncology with a time-to-event primary endpoint (hearing preservation hazard ratio) and reports primary results. However, it is not eligible because the intervention is not drug-containing (it compares two radiotherapy fractionation schedules, not a drug). Additionally, the trial phase is not explicitly confirmed as Phase III or a definitive trial in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Randomized Comparison of High-Dose-Rate and Low-Dose-Rate Prostate Brachytherapy Combined With External Beam Radiation Therapy for Unfavorable Prostate Cancer: Efficacy Results After Median Follow-up of 74 Months. PMID 40187573 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 The trial is randomized, human, oncologic, and reports time-to-event efficacy endpoints. However, it is ineligible because the intervention is not a drug-containing one; it compares two radiation therapy modalities (HDR vs. LDR brachytherapy). Additionally, the phase of the trial is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Prognostic Analysis of Chemoradiation Therapy Versus Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results From a Prospective Randomized Control Study. PMID 40185210 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group. PMID 40185209 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 The record describes a Phase III randomized trial in pediatric oncology (rhabdomyosarcoma) but evaluates radiotherapy dose escalation and modalities (proton vs. photon), not a drug-containing intervention. The reported endpoints are local failure rates (percentages), not time-to-event endpoints like OS, PFS, DFS, or Kaplan-Meier analyses. Therefore, it does not meet the drug intervention or time-to-event efficacy criteria. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program. PMID 40184206 · Inflamm Bowel Dis · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma. PMID 40164352 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Preventing pulmonary complications after laparoscopic colorectal surgery: a lung-protective protocol vs. standard care: A randomised controlled trial. PMID 40159954 · Eur J Anaesthesiol · 2025-Sep-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial. PMID 40109195 · Haematologica · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial. PMID 40079105 · Haematologica · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial. PMID 41647992 · ESMO Gastrointest Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study. PMID 41647991 · ESMO Gastrointest Oncol · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations. PMID 41647988 · ESMO Gastrointest Oncol · 2025-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Ascorbate for Organ Dysfunction in Critically Ill Patients With Sepsis: The Phase 2b ASTER Trial. PMID 41574117 · CHEST Crit Care · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Development, usability, and randomized pilot feasibility study of a mobile application prototype supporting self-management of accidental bowel leakage. PMID 41311646 · Continence (Amst) · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Immunotherapy in Treating Metastatic Melanoma: A Randomized Controlled Trial. PMID 41164606 · J Pharm Bioallied Sci · 2025-Sep The record describes a randomized trial in oncology with a drug intervention and primary time-to-event endpoints (PFS, OS). However, the abstract does not explicitly state the trial phase (e.g., Phase III, Phase II/III). Per adjudication rules, phase cannot be inferred. Therefore, the 'phase3_or_definitive' criterion cannot be established, making the record ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tenapanor for Irritable Bowel Syndrome With Constipation (IBS-C): A Systematic Review of Randomized Trials Assessing Food and Drug Administration (FDA) Composite Response, Durability, and Risk-of-Bias (RoB-2). PMID 41158898 · Cureus · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |